摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2,6-diethylphenyl)-1,2,3,4-tetrahydroisoquinoline-1,3-dione | 202200-23-5

中文名称
——
中文别名
——
英文名称
2-(2,6-diethylphenyl)-1,2,3,4-tetrahydroisoquinoline-1,3-dione
英文别名
PIQ-22;N-(2,6-diethylphenyl)-homophthalimide;2-(2,6-diethylphenyl)-4H-isoquinoline-1,3-dione
2-(2,6-diethylphenyl)-1,2,3,4-tetrahydroisoquinoline-1,3-dione化学式
CAS
202200-23-5
化学式
C19H19NO2
mdl
——
分子量
293.365
InChiKey
RXXGGIYKMYOUPC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    471.2±45.0 °C(Predicted)
  • 密度:
    1.172±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    37.4
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(2,6-diethylphenyl)-1,2,3,4-tetrahydroisoquinoline-1,3-dione 在 palladium on activated charcoal sodium tetrahydroborate 、 氢气 作用下, 生成
    参考文献:
    名称:
    具有高邻苯二甲酰亚胺骨架的嘌呤霉素敏感性氨基肽酶的特异性抑制剂:目标分子的鉴定和构效关系研究。
    摘要:
    发现2-(2,6-二乙基苯基)-1,2,3,4-四氢异喹啉-1,3-二酮(2:PIQ-22)是嘌呤霉素敏感性氨基肽酶(PSA)的有效和特异性抑制剂。Lineweaver-Burk图分析表明,PSA被PIQ-22抑制为非竞争性方式。结构-活性关系研究表明,PIQ-22骨架的环状酰亚胺部分中的亚氨基苯甲酰基酮基的互变异构对于抑制活性很重要。
    DOI:
    10.1016/s0968-0896(00)00231-5
  • 作为产物:
    参考文献:
    名称:
    具有高邻苯二甲酰亚胺骨架的嘌呤霉素敏感性氨基肽酶的特异性抑制剂:目标分子的鉴定和构效关系研究。
    摘要:
    发现2-(2,6-二乙基苯基)-1,2,3,4-四氢异喹啉-1,3-二酮(2:PIQ-22)是嘌呤霉素敏感性氨基肽酶(PSA)的有效和特异性抑制剂。Lineweaver-Burk图分析表明,PSA被PIQ-22抑制为非竞争性方式。结构-活性关系研究表明,PIQ-22骨架的环状酰亚胺部分中的亚氨基苯甲酰基酮基的互变异构对于抑制活性很重要。
    DOI:
    10.1016/s0968-0896(00)00231-5
点击查看最新优质反应信息

文献信息

  • Medicinal composition
    申请人:Ishihara Sangyo Kaisha Ltd.
    公开号:US06429212B1
    公开(公告)日:2002-08-06
    It is to provide a cyclic imide derivative which is useful as an active ingredient of a pharmaceutical composition. A pharmaceutical composition which comprises, a cyclic imide derivative represented by the general formula (I): wherein Q1 is a single bond, —CH2—, —O—, —S— or —NH—, each of Q2 and Q3 is —C(O)—, —C(S)— or —CH2—, provided that at least one of Q2 and Q3 is —C(O)— or —C(S)—, Z is a single bond or a lower alkanediyl group, R is an aryl group which may be substituted or a cycloalkyl group which may be substituted, X is a nitro group, an amino group which may be acylated, a cyano group, a trifluoromethyl group, a hydroxyl group, a halogen atom, an alkyl group, an alkoxy group or an alkylthio group, m is an integer of from 0 to 4, and when m is 2 or above, X may be the same or different, or its salt.
    提供的是一种环状亚胺衍生物,它作为药物组合物的有效成分很有用。所述药物组合物包含由通式(I)表示的环状亚胺衍生物: 其中Q1是单键、-CH2-、-O-、-S-或-NH-,Q2和Q3每个是-C(O)-、-C(S)-或-CH2-,前提是Q2和Q3中至少有一个是-C(O)-或-C(S)-,Z是单键或低级脂肪二烯基团,R是可以被取代的芳基团或可以被取代的环烷基团,X是硝基团、可能被酰化的氨基团、氰基团、三氟甲基团、羟基团、卤素原子、烷基团、烷氧基团或烷硫基团,m是从0到4的整数,当m为2或以上时,X可以是相同的或不同的,或其盐。
  • Thalidomide as a Nitric Oxide Synthase Inhibitor and Its Structural Development
    作者:Rumiko Shimazawa、Hiroko Sano、Aya Tanatani、Hiroyuki Miyachi、Yuichi Hashimoto
    DOI:10.1248/cpb.52.498
    日期:——
    Thalidomide has been found to exhibit weak nitric oxide synthase (NOS)-inhibitory activity. Structural development studies of thalidomide showed that some N-2,6-dimethylphenylhomophthalimide analogs possess NOS-inhibiting activity.
    沙利度胺被发现具有弱的硝氧化酶(NOS)抑制活性。沙利度胺的结构开发研究表明,一些N-2,6-二甲基苯基同苯二甲酰亚胺类似物具有抑制NOS的活性。
  • Pharmaceutical composition
    申请人:Ishihara Sangyo Kaisha Ltd.
    公开号:US06515129B1
    公开(公告)日:2003-02-04
    It is to provide a cyclic imide derivative which is useful as an active ingredient of a pharmaceutical composition. A pharmaceutical composition which comprises, a cyclic imide derivative represented by the general formula (I): wherein Q1 is a single bond, —CH2—, —O—, —S— or —NH—, each of Q2 and Q3 is —C(O)—, —C(S)— or —CH2—, provided that at least one of Q2 and Q3 is —C(O)— or —C(S)—, Z is a single bond or a lower alkanediyl group, R is an aryl group which may be substituted or a cycloalkyl group which may be substituted, X is a nitro group, an amino group which may be acylated, a cyano group, a trifluoromethyl group, a hydroxyl group, a halogen atom, an alkyl group, an alkoxy group or an alkylthio group, m is an integer of from 0 to 4, and when m is 2 or above, X may be the same or different, or its salt.
    它是为了提供一种环内酰亚胺衍生物,该衍生物可用作药物组合物的活性成分。该药物组合物包括由通式(I)表示的环内酰亚胺衍生物,其中Q1是单键,-CH2-,-O-,-S-或-NH-,Q2和Q3每个是-C(O)-,-C(S)-或-CH2-,但至少有一个是-C(O)-或-C(S)-,Z是单键或低级脂肪二基基团,R是芳基基团,可以被取代或环烷基团,可以被取代,X是硝基基团,可以酰化的氨基基团,氰基,三氟甲基基团,羟基,卤素原子,烷基,烷氧基或烷硫基,m是0到4的整数,当m为2或以上时,X可以相同或不同,或其盐。
  • METHOD FOR ACTIVATING REGULATORY T-CELLS
    申请人:Ansorge Siegfried
    公开号:US20110117069A1
    公开(公告)日:2011-05-19
    The invention relates to a method for activating regulatory t-cells (Treg-cells) of the human or animal body, comprising a step of bringing into contact the regulatory t-cells (Treg-cells) in a suitable liquid medium with one or a plurality of inhibitors of alanyl-amino peptidase (amino peptidase N; APN) and/or with one or a plurality of inhibitors of peptidases with the same substrate specificity to induce a suppressive effect of the regulatory t-cells (Treg-cells).
  • US6429212B1
    申请人:——
    公开号:US6429212B1
    公开(公告)日:2002-08-06
查看更多